---
title: "MapLight Therapeutics plunges 71% as schizophrenia drug fails dosing test"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293967660.md"
description: "MapLight Therapeutics (MPLT) tumbles 71% during regular trading after its schizophrenia candidate ML-007C-MA failed a dosing test."
datetime: "2026-07-27T19:40:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293967660.md)
  - [en](https://longbridge.com/en/news/293967660.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293967660.md)
generator: "portal-rs"
---

# MapLight Therapeutics plunges 71% as schizophrenia drug fails dosing test

MapLight Therapeutics(MPLT.US) 盘中跌近**71%**，现报**10.725 美元**。

此次暴跌源于公司精神分裂症候选药物 ML-007C-MA 未能通过一次给药测试。消息公布后，该股在常规交易中大幅下挫，成交量显著放大。

MapLight Therapeutics 此次临床测试失败引发投资者对公司研发前景的担忧，导致股价出现剧烈波动。

### Related Stocks

- [MPLT.US](https://longbridge.com/en/quote/MPLT.US.md)

## Related News & Research

- [MapLight Therapeutics to present at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/298444988.md)
- [Catalyst4 acquires $50.07 million of MapLight Therapeutics common shares](https://longbridge.com/en/news/296276892.md)
- [MapLight Q2 FY26 net loss widens to $60.19 million; R&D expenses rise to $53.44 million](https://longbridge.com/en/news/295839597.md)
- [MapLight Therapeutics prices USD 150 million PIPE at USD 11.38 a share](https://longbridge.com/en/news/295804908.md)
- [Maplight Therapeutics CSO Lillie James Woodruff sells 22,082 shares for $276,908.28](https://longbridge.com/en/news/294889583.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**